Peptide Encyclopedia / Survodutide
EncyclopediaSurvodutide is a dual glucagon and GLP-1 receptor agonist, designed to curb appetite and blood sugar while raising energy expenditure and easing liver fat. Boehringer Ingelheim and Zealand Pharma are testing it as a once-weekly injection for obesity and MASH, and it holds FDA Breakthrough Therapy status for MASH fibrosis, but it stays in trials and is not FDA-approved. Below you'll find reported dosing, safety, and legal status. Educational only, not medical advice.
| Category | GLP-1 / Metabolic |
| Regulatory status | Investigational; not FDA-approved. |
A dual glucagon receptor and GLP-1 receptor agonist that reduces appetite and improves glycemia while leveraging glucagon agonism to increase energy expenditure and reduce hepatic steatosis.
uncertain from public data; designed for once-weekly subcutaneous administration. Commonly reported use/dosing: No approved protocol. In trials given as once-weekly subcutaneous injection with titration; investigational only and not a validated regimen.
Investigational; not FDA-approved. Developed by Boehringer Ingelheim/Zealand Pharma for obesity and MASH (NASH); granted FDA Breakthrough Therapy designation for MASH-related fibrosis but not approved.
GI adverse effects (nausea, vomiting, diarrhea), possible increased heart rate; long-term cardiovascular and metabolic safety still under investigation.
Phase 2/3 clinical development for obesity and MASH; not approved.
PepWise is an informational and educational tracking tool, not medical advice and not a medical device. Survodutide may be experimental, restricted, or prescription-only; many research peptides are not FDA-approved. Consult a licensed healthcare provider before starting, changing, or stopping any protocol. Operated by STC Consulting, Inc.
